What will happen at the end of the main part of the study?

The results will be published in health or scientific journals, on websites (including www.ClinicalTrials.gov), and will be discussed at major conferences. Others will learn from the results, which we hope will show that more lives can be saved by using empagliflozin andvicadrostat (BI 690517). No individual participant will be identified in any report or publication.

We will try our best to inform participants and their GPs of the study results and any related publicity. We will use study newsletters and videos on the study website to inform people about what the study shows.

Your contribution to the study could be even more valuable if we have your permission to get information about your health after your very last study appointment. Therefore, we will ask for your permission to use your contact details, such as your email address, to continue to communicate with you after the study has ended. This way we can learn about any longer-term health effects of the study pills. This might include a questionnaire or phone call once a year, review of your medical notes, flagging with local registries or an interview with your local clinical team. For example, scientists can continue to get information about your health, such as details from your doctors, NHS England, the NHS Diabetic Eye Screening Programme (or other central NHS registry), and the UK Renal Registry.